about
The impact of diabetes on the pathogenesis of sepsisDiagnosis of scrub typhusLimited role for ASC and NLRP3 during in vivo Salmonella Typhimurium infection.Neutrophil extracellular traps in the host defense against sepsis induced by Burkholderia pseudomallei (melioidosis)Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial.Pharmacokinetic Interactions between Tafenoquine and Dihydroartemisinin-Piperaquine or Artemether-Lumefantrine in Healthy Adult SubjectsEstimation of the Antirelapse Efficacy of Tafenoquine, Using Plasmodium vivax Genotyping.Time-to-detection in culture predicts risk of Mycobacterium tuberculosis transmission: a cohort study.Predictors of contact tracing completion and outcomes in tuberculosis: a 21-year retrospective cohort study.The case against exchange transfusion has yet to be proved.Application of the Stable Isotope Label Approach in Clinical Development-Supporting Dissolution Specifications for a Commercial Tablet Product with Tafenoquine, a Long Half-life CompoundThrombocytopenia Impairs Host Defense Against Burkholderia pseudomallei (Melioidosis)Population Pharmacokinetics of Tafenoquine, a Novel AntimalarialSingle-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax MalariaTafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax MalariaTafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria. ReplyRandomized Placebo-Controlled Trial Evaluating the Ophthalmic Safety of Single-Dose Tafenoquine in Healthy Volunteers
P50
Q24616935-9E8D33CD-ADBE-4ABB-AEF2-F325C311289EQ24634683-CFBC06E6-AE78-4CA4-BEB8-B7AA055EFD33Q34570348-E18374F1-D223-44FA-A0CB-F92361A5B28FQ36369202-91F81823-6E63-42DF-9448-E1B80FF8F4C1Q36591835-C65ACF07-2143-4991-BCD2-2954BBBE8019Q37428670-E01109A1-F1DC-4AEC-A7B9-3AE69A19A465Q38320074-44971A4C-7D9F-4C52-92D1-969255C43625Q39314984-15E1606C-0A5E-4C7B-953F-92B32C92046EQ39433388-C437F2A7-B026-43A7-AB5E-DD3E9C9F6CD4Q42778021-2F058053-8474-4319-BCB1-BB447B8BDDEFQ56363446-9E62FB87-3E88-4EA8-987E-7ACF39C95A0BQ57476223-E5137F97-E11D-4C25-8B23-1C2E0E62F825Q57789663-C860FBBA-9438-488E-9BE0-82D494B56F31Q61920255-A3D9ACF2-D73D-46C1-B2C0-D37A04B877F2Q63634450-04176408-08BC-479B-AF45-4C051A3E64C4Q91854484-21AF7E25-BE91-4237-AA1F-B94B4B72FE93Q92674900-D3F9369A-3E46-401E-BBAF-E33407C7DDF9
P50
description
investigador
@es
researcher
@en
name
Gavin C K W Koh
@en
type
label
Gavin C K W Koh
@en
prefLabel
Gavin C K W Koh
@en
P31
P496
0000-0002-7336-1566